Hunan Er-Kang Pharmaceutical Co., Ltd reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was CNY 1,766.36 million compared to CNY 1,859.91 million a year ago. Revenue was CNY 1,783.12 million compared to CNY 1,870.54 million a year ago.

Net loss was CNY 195.32 million compared to net income of CNY 45.94 million a year ago. Basic loss per share from continuing operations was CNY 0.0947 compared to basic earnings per share from continuing operations of CNY 0.0223 a year ago. Diluted loss per share from continuing operations was CNY 0.0947 compared to diluted earnings per share from continuing operations of CNY 0.0223 a year ago.